Arkolith/Insider Trading/SYRE/Form 4

Burrows Scott L

Chief Financial OfficerSpyre Therapeutics, Inc. (SYRE) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$102K
Net Open-Market Flow
-$102K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2026Sell(S)200$41.66$8K98K
Mar 3, 2026Sell(S)2K$40.56$93K98K
Mar 3, 2026Option exercise(M)3K$14.50$36K100K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 3, 2026Option exercise(M)3K—$0402K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001636282-26-000028) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML